202 related articles for article (PubMed ID: 11929819)
1. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
[TBL] [Abstract][Full Text] [Related]
3. Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo.
Ramachandra S; D'Souza SS; Gururaj AE; Shaila MS; Salimath BP
J Gene Med; 2009 May; 11(5):422-34. PubMed ID: 19266483
[TBL] [Abstract][Full Text] [Related]
4. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
[TBL] [Abstract][Full Text] [Related]
5. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
6. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.
Davidoff AM; Nathwani AC; Spurbeck WW; Ng CY; Zhou J; Vanin EF
Cancer Res; 2002 Jun; 62(11):3077-83. PubMed ID: 12036917
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
Byrne AT; Ross L; Holash J; Nakanishi M; Hu L; Hofmann JI; Yancopoulos GD; Jaffe RB
Clin Cancer Res; 2003 Nov; 9(15):5721-8. PubMed ID: 14654557
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
Luo JC; Toyoda M; Shibuya M
Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
[TBL] [Abstract][Full Text] [Related]
10. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
Kryczek I; Lange A; Mottram P; Alvarez X; Cheng P; Hogan M; Moons L; Wei S; Zou L; Machelon V; Emilie D; Terrassa M; Lackner A; Curiel TJ; Carmeliet P; Zou W
Cancer Res; 2005 Jan; 65(2):465-72. PubMed ID: 15695388
[TBL] [Abstract][Full Text] [Related]
11. [Effect of soluble vascular endothelial growth factor (VEGF) receptor gene (sflt-1) and antisense VEGF nucleotide on neovascularization].
Mi J; Wang JH; Chen SS
Ai Zheng; 2002 May; 21(5):464-8. PubMed ID: 12452033
[TBL] [Abstract][Full Text] [Related]
12. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector.
Takei Y; Mizukami H; Saga Y; Yoshimura I; Hasumi Y; Takayama T; Kohno T; Matsushita T; Okada T; Kume A; Suzuki M; Ozawa K
Int J Cancer; 2007 Jan; 120(2):278-84. PubMed ID: 17066424
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
Mahendra G; Kumar S; Isayeva T; Mahasreshti PJ; Curiel DT; Stockardt CR; Grizzle WE; Alapati V; Singh R; Siegal GP; Meleth S; Ponnazhagan S
Cancer Gene Ther; 2005 Jan; 12(1):26-34. PubMed ID: 15359287
[TBL] [Abstract][Full Text] [Related]
15. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Mahasreshti PJ; Kataram M; Wang MH; Stockard CR; Grizzle WE; Carey D; Siegal GP; Haisma HJ; Alvarez RD; Curiel DT
Clin Cancer Res; 2003 Jul; 9(7):2701-10. PubMed ID: 12855650
[TBL] [Abstract][Full Text] [Related]
16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K
Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839
[TBL] [Abstract][Full Text] [Related]
18. [Effects of interleukin-12 transfection on proliferation of ovarian cancer SKOV3 cells in vitro and in vivo].
Wang J; Zhang CQ; Liu J; Sui LH
Ai Zheng; 2007 Dec; 26(12):1292-8. PubMed ID: 18076789
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.
Middeke M; Hoffmann S; Hassan I; Wunderlich A; Hofbauer LC; Zielke A
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):386-92. PubMed ID: 12518248
[TBL] [Abstract][Full Text] [Related]
20. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
Narita K; Staub J; Chien J; Meyer K; Bauer M; Friedl A; Ramakrishnan S; Shridhar V
Cancer Res; 2006 Jun; 66(12):6025-32. PubMed ID: 16778174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
